Partnership Expansion Leverage Avadel’s integration into Alkermes to explore co-development or licensing opportunities, especially in neuroscience and sleep disorder therapeutics, aligning joint capabilities for broader market reach.

Clinical Collaboration Target opportunities around Lumryz and related CNS programs by proposing joint clinical trials, real-world evidence studies, or patient-reported outcome research with access to Swoop Communities data to better understand patient needs and language.

Global Footprint Capitalize on Avadel’s Ireland base and Alkermes’ U.S. footprint to propose cross-border commercialization, regulatory strategy support, and market access packages for European and North American launches.

Strategic Licensing Propose exclusive or co-exclusive licensing deals with XWPharma or similar partners to expand portfolio reach, particularly for formulations or delivery platforms aligned with Avadel’s focus areas.

Investor and Market Insights Offer services around market intelligence and investor-ready data leveraging management visibility and recent funding signals, to support strategic communications and partner due diligence with potential buyers or licensees.